Aortic valve stenosis (AS) will become more common as the population ages. Once symptoms occur, the prognosis is poor. Aortic valve replacement (AVR) has been the standard of care, improving symptoms and prolonging survival. A significant proportion of patients, however, do not undergo AVR due to increased surgicalrisk. The technology of transcatheter aortic valve implantation (TAVI) emerged in 2002 and offered some of these patients an alternative therapy. A randomised (PARTNER) trial has shown that TAVI (using the Edwards-Sapien transcatheter heart valve) was superior to medical therapy (including balloon aortic valvuloplasty) in inoperable patients with a significant reduction in all-cause mortality at one year. For high surgical-risk patients, TAVI demonstrated non-inferiority to open AVR, with similar all-cause mortality at one year. Currently two devices, the Edwards-Sapien and the CoreValve transcatheter heart valves, are in clinical use and are undergoing further trials. Device improvements will be required to enhance procedural success and safety and longer term data would be required to understand the longevity of these valves. Further trial data would be required to compare TAVI and open AVR in moderate surgical-risk patients if this technology were to become a more common therapy.
INTrODUCTION
The prevalence of aortic valve stenosis (AS) increases with advancing age, and is present in 4.6% of adults ≥75 years of age 1 . With an ageing population, the number of patients with AS will increase. Once symptoms occur, the prognosis is poor with medical therapy, with a 50% mortality rate between one to two years 2, 3 . Surgical aortic valve replacement (AVR), with an average operative mortality of 3% is the treatment of choice for the majority of these patients, with the relief of symptoms and improved survival 4 .
However, in a significant number of patients, mainly the very elderly and those with severe comorbidities, the risk of AVR is often considered to be much higher and these patients are therefore not offered surgery [5] [6] [7] . The Euroheart survey found that up to 33% of patients with symptomatic severe AS were denied surgery, with advanced age and left ventricular dysfunction being the main factors 8 . Although balloon aortic valvuloplasty (BAV) can provide temporary symptomatic relief 9 , it does not confer survival benefit 10 .
Recently, an alternative to surgical AVRpercutaneous transcatheter aortic valve implantation (TAVI) -has emerged. In 2002, the first-in-man transcatheter aortic valve implantation was performed by Alain Cribier, the pioneering French cardiologist, and coworkers 11 . They demonstrated that the nonsurgical implantation of a prosthetic heart valve could be achieved with immediate and mid-term haemodynamic and clinical improvement. This novel procedure generated intense interest within the cardiology and cardiac surgery communities, and technological advancements have been made exponentially 12, 13 .
CUrrENT STATUS OF AOrTIC TrANSCATHETEr HEArT VALVES (THVs)
There are two THVs in clinical use with both having achieved the European CE mark (approval for commercial sale) in 2007. The balloon-expandable Cribier-Edwards valve (developed by Cribier et al), is now known as the Edwards-Sapien valve (Edwards Lifesciences Inc, California, USA). The prosthesis consists of three bovine pericardial leaflets mounted within a tubular, slotted, stainless steel (now cobalt chromium -Sapien XT) balloon expandable stent ( Fig. 1 ). This valve can be implanted via a retrograde transfemoral transarterial route (Fig. 2 ) or a transapical approach (by simply inverting the valve during the valve crimping process) ( Fig. 3) . The results of a FDA (Food and Drug Administration) sanctioned randomised trial using this valve have been published 14, 15 .
The other prosthesis in clinical use is the selfexpandable CoreValve THV (Corevalve, Medtronic, Minnesota, USA). This prosthesis consists of three porcine pericardial tissue leaflets mounted and sutured in a self-expanding nitinol stent (Fig. 4 ). The stent frame is longer (50 mm), with the lower portion having a high radial force to expand and exclude the calcified aortic leaflets; the middle portion carries the valve -the leaflets are supraannular -and is constrained to avoid obstructing the coronary arteries; and the upper portion is flared to fixate the stent in the ascending aorta. This prosthesis is implanted via the retrograde transfemoral transarterial route or a transsubclavian artery approach and very recently, a direct trans-aortic technique.
Within the short span of time since the CE mark approval, over 70,000 TAVIs have been performed worldwide using both devices (data courtesy of Edwards Lifesciences and Medtronic CoreValve). Published data suggest that the clinical results between the two devices are mostly equivalent with a 30-day stroke rate of approximately 3% and mortality rates of between 6% to 10% 16, 17 , although the CoreValve device results in a higher postprocedure pacemaker implantation requirement of up to 30% as compared to 7% for the Edwards-Sapien device 16, 18 . 
rESULTS FrOM rANDOMISED TrIALS
The PARTNER (Placement of aortic transcatheter valves) trial design consisted of two separate cohorts, randomising a total of over 1000 patients. The PARTNER trial cohort B randomised nonoperable patients with symptomatic severe AS to either TAVI (transfemoral route only) or medical therapy with or without balloon aortic valvuloplasty (standard therapy) 14 . All-cause mortality at one year, the primary endpoint, occurred in 30.7% of patients with TAVI versus 50.7% of patients with standard therapy (HR 055, P <0.001). There was also significant improvement of functional status in patients who had undergone TAVI at one year (NYHA III-IV was 25.2% in the TAVI group versus 58% in the standard therapy group, P <0.001). As expected, there were procedural complications associated with TAVI. At 30 days, there was a higher incidence of major strokes (5.0% vs 1.1%, P=0.06), and major vascular complications (16.2% vs 1.1%, P <0.001). Thus this trial demonstrated that in patients with inoperable symptomatic severe AS, TAVI, as compared with standard therapy, significantly reduced the rates of all-cause mortality, the composite of all-cause mortality and repeat hospitalisation, and cardiac symptoms, despite the higher incidence of major stokes and major vascular events. Another important lesson from this trial was that contemporary medical therapy including BAV did not alter the dismal prognosis of symptomatic severe AS with a one year mortality of 50%. TAVI should now be considered the standard of care for inoperable patients with symptomatic severe AS.
The PARTNER trial cohort A compared highsurgical risk patients to either TAVI (transfemoral or transapical route) or open aortic valve replacement (AVR) 15 . The primary hypothesis was that TAVI would be non-inferior to AVR at one year. Highsurgical risk was determined by calculating the STS (Society of Thoracic Surgeons) risk score (defined as STS score ≥10) or if two cardiac surgeons assessed the patient to be at increased risk for AVR. All-cause mortality were 3.4% (TAVI) and 6.5% (AVR) at 30 days (P=0.07) and 24.2% and 26.8%, respectively, at one year (P=0.44), demonstrating the noninferiority of TAVI as compared to AVR. The rates of major stroke were 3.8% (TAVI) and 2.1% (AVR) at 30 days (P=0.20) and 5.1% and 2.4%, respectively, at one year (P=0.07). At 30 days, major vascular complications were significantly more frequent with TAVI (11.0% vs. 3.2%, P <0.001) whereas major bleeding (19.5% vs. 9.3%, P <0.001) and new-onset atrial fibrillation (16.0% vs. 8.6%, P=0.006) were more frequent with AVR. Thus for high-surgical risk patients with symptomatic severe AS, TAVI can be considered an alternative treatment modality with different procedural risks.
It must be remembered that the PARTNER trial was conducted using the first generation Edwards-Sapien device, the RetroFlex 1. Outside of the United States (USA), the device has evolved several generations (RetroFlex 1, RetroFlex 2, RetroFlex 3, NovaFlex and currently NovaFlex-plus), with the reduction in device profile and delivery sheath size (22 French size, approximately 8.5mm outer diameter to 16 French size, approximately 6.5mm in outer diameter). These improvements will undoubtedly make the procedure safer, reducing vascular and other complications.
CoreValve has also recently started a FDA sanctioned randomised trial in the USA; however results would not be expected until 2014.
TAVI IN SINGAPOrE
This technology became available to Asia in February 2009 when our institution became the first centre in Asia to perform the procedure 19, 20 , using the Edwards-Sapien valve. Subsequently, in January 2011, our institution became the first centre in Asia to also have the CoreValve available, increasing the options for our patients.
Patients are considered for TAVI if they are at highsurgical risk (STS score ≥10 or logistic EuroSCORE -this is a cardiac surgical risk scoring system developed by the Europeans -≥20%) or if our cardiac surgeons assess the patient to be at an increased risk. Some factors not accounted for in the STS score or the EuroSCORE are, for example, porcelain aorta, previous chest radiation, presence of patent coronary artery bypass grafts, liver cirrhosis, frailty and so forth.
Seventy-two patients have undergone the procedure at our institution, 50 via the transfemoral route, 19 via the transapical approach and 3 via the direct aortic route (unpublished data). Overall, 30-day mortality is 9.7% (transfemoral procedure mortality 6%); there were no strokes.
TAVI -EXTENDING THE INDICATIONS
Currently, both devices are indicated for patients Proceedings of Singapore Healthcare  Volume 22  Number 2  2013 with degenerative severe AS, where the valve is tricuspid. In the PARTNER trial, bicuspid aortic valves were exclusion criteria. The concern is that the transcatheter valves would not be able to achieve a circular expansion in a bicuspid morphology. In well selected patients, anecdotal evidence seems to suggest that TAVI in bicuspid AS appear feasible with satisfactory results 21, 22 .
As life expectancy increases, degenerated bioprosthetic valves (either stenosed or regurgitant) will become more frequent. Surgery to replace these valves invariably carries a higher risk than the initial procedure due to increased age and chest wall scarring. TAVI may offer a viable alternative for some of these patients (valve-invalve procedure). Early reports demonstrate that the Edwards-Sapien THV and the CoreValve can be used for degenerated aortic bioprosthetic valves 23, 24 ; in addition, due to the design and simplicity of the Edwards-Sapien THV, it can also be used to replace degenerated bioprosthetic valves in the mitral, tricuspid and pulmonary positions 23 .
We have performed several cases of TAVI implantation in patients with a severely stenosed aortic bioprosthetic valve using both the CoreValve and Sapien THVs, resulting in significant haemodynamic improvement (unpublished data).
It is also conceivable that patients who have undergone TAVI would also be able to have another THV implanted in the future should the bioprosthesis degenerate. It has been shown that implantating a THV-in-THV was feasible with sustained haemodynamics and preserved valve function for up to three years 12 (now up to seven years, Carlos Ruiz, MD, personal communication).
TAVI -THE FUTUrE
There are plans to test this technology (Edwards-Sapien valve) in moderate surgical-risk patients and this trial is currently ongoing. This would constitute a big proportion of patients with symptomatic severe AS. With excellent surgical AVR results, it is a challenge that TAVI has to match if this therapy is to become more common.
Current surgical aortic bioprosthetic valves have been shown to last an average of 15 years, with greater longevity in patients aged more than 65 years 25 . Further durability data would also be required of current THVs to prove that the transcatheter valves are as durable.
Technological improvements to the current devices will continue to be made, with improving device profile and ease of use. Several other transcatheter valves are being developed and some have achieved first-in-man implantation 12, 13 . All these technological innovations will make the current and future transcatheter valves more deliverable, repositionable and retrievable, enhancing the safety and success of the procedure.
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